Rogers et al. (2009) performed a randomised controlled trial of a physical activity behaviour change intervention for 41 women with breast cancer who were receiving an aromatase inhibitor or selective oestrogen receptor modulator and observed no difference in self-reported cognitive functions after the intervention [70]. This evidence concerns the gene CYP19A1 and breast cancer.